Maternal microbiome in preeclampsia pathophysiology and implications on offspring health

Abstract

Preeclampsia is a devastating hypertensive pregnancy disorder that currently affects 2%–8% of pregnancies worldwide. It is associated with maternal and fetal mortality and morbidity and adverse health outcomes both in mom and offspring beyond pregnancy. The pathophysiology is not completely understood, and there are no approved therapies to specifically treat for the disease, with only few therapies approved to manage symptoms. Recent advances suggest that aberrations in the composition of the microbiome may play a role in the pathogenesis of various diseases including preeclampsia. The maternal and uteroplacental environments greatly influence the long‐term health outcomes of the offspring through developmental programming mechanisms. The current review summarizes recent developments on the role of the microbiome in adverse pregnancy outcomes with a focus on preeclampsia. It also discusses the potential role of the maternal microbiome in fetal programming; explores gut‐targeted therapeutics advancement and their implications in the treatment of preeclampsia.

Abstract

Preeclampsia is a devastating hypertensive pregnancy disorder with maternal and fetal mortality and morbidity, and the maternal and uteroplacental environments greatly influence the long‐term health outcomes of the mom and offspring. Recent advances suggest that aberrations in the composition of the microbiome may play a role in the pathogenesis of preeclampsia. The current review summarizes recent developments on the role of the microbiome in adverse pregnancy outcomes with a focus on preeclampsia and explores gut‐targeted therapeutics advancement and their implications in the treatment of preeclampsia.